Pityriasis rosea in otherwise asymptomatic confirmed COVID-19–positive patients: A report of 2 cases

Johansen, Maija; Chisolm, Sarah; Aspey, Laura; Brahmbhatt, Meera

doi:10.1016/j.jdcr.2020.10.035

Cited by 25 publications

(41 citation statements)

References 4 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with previous reports, [1][2][3][4][5][6][7][8][9] our case had shown the different phases of the evolution of the PR manifestation, highlighting how the cutaneous lesions during the acute phase of COVID-19 assumed a more erythematous and purpuric appearance, as indication of a general inflammatory state associated with the SARS-CoV-2 infection.…”

contrasting

confidence: 56%

See 1 more Smart Citation

Pityriasis rosea infection in a COVID ‐19 patient successfully treated with systemic steroid and antihistamine via telemedicine: Literature update of a possible prodromal symptom of an underlying SARS‐CoV ‐2 infection

Paolino

Nicola

Cantisani

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

contrasting

confidence: 56%

“…2 Different cases of pityriasis rosea (PR) and pityriasis rosea-like eruptions have been recently reported. [1][2][3][4][5][6][7][8][9][10] These observations correspond to the fact that HHV-6…”

mentioning

confidence: 97%

Pityriasis rosea infection in a COVID ‐19 patient successfully treated with systemic steroid and antihistamine via telemedicine: Literature update of a possible prodromal symptom of an underlying SARS‐CoV ‐2 infection

Paolino

Nicola

Cantisani

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Pityriasis rosea as a manifestation of Covid‐19 although has been reported, 8 , 9 our patient did not have any history of established Covid‐19 or symptoms suggestive of the same prior to immunization. Furthermore, appearance of the rash within a very short duration after vaccination makes the causal relationship between the two appear quite plausible.…”

Section: Figurementioning

confidence: 57%

Post Covid‐19 vaccination papulovesicular pityriasis rosea‐like eruption in a young male

Adya

Inamadar

Albadri

2021

Dermatologic Therapy

View full text Add to dashboard Cite

“…Johansen et al reported in the literature 2 cases of PR in female patients with phototype III and IV, with asymptomatic forms of COVID-19, in which the cutaneous manifestations preceded the diagnosis of SARS-CoV-2 infection. [ 15 ]…”

Section: Discussionmentioning

confidence: 99%

Pityriasis rosea Gibert triggered by SARS-CoV-2 infection

2021

View full text Add to dashboard Cite

Rationale: Pityriasis rosea Gibert is an erythematous-papulosquamous dermatosis that frequently occurs in young adults. The etiopathogenesis of PR is still unknown, but is frequently associated with episodes of upper respiratory tract infections. It is likely that a new viral trigger of pityriasis rosea is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patient concerns: We present the case of a female patient in whom the diagnosis of pityriasis rosea led to the investigation and diagnosis of the SARS-CoV-2 infection. The patient presented to the Department of Dermatology for a 3 week duration of an extremely pruritic erythematous-squamous lesion, initially on the trunk and upper limbs, with extension to the lower limbs in the last week and the lesion respected the cephalic extremity, palms, and soles. One week before the rash, respiratory tract infection symptomatology was observed by the patient. At home, she underwent systemic treatment with antihistamines and topical medication with dermatocorticosteroids. The evolution was unfavorable, with the spread of the lesions and the accentuation of the pruritus. Diagnoses: Considering the actual epidemiological context, we performed a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay from nasal and pharyngeal swabs for coronavirus disease 2019 (COVID-19) to investigate the PR etiology. The patient had a positive RT-PCR result, and was confirmed with SARS-CoV-2 infection. Interventions: Treatment was initiated with systemic corticosteroid therapy - hydrocortisone hemisuccinate 200 mg/day for 7 days, and loratadine 10 mg 2 times a day. Also, topical medication with dermatocorticosteroids and emollients was associated. Outcome: Under the treatment that was initiated a partial remission of the lesions after 7 days was observed. Lessons: Our reported case adds to the other findings regarding the association of PR with SARS-CoV-2 infection, in the context of the pandemic, suggesting the need to test patients with PR skin lesions for SARS-CoV-2 infection.

show abstract

Pityriasis rosea in otherwise asymptomatic confirmed COVID-19–positive patients: A report of 2 cases

Cited by 25 publications

References 4 publications

Pityriasis rosea infection in a COVID ‐19 patient successfully treated with systemic steroid and antihistamine via telemedicine: Literature update of a possible prodromal symptom of an underlying SARS‐CoV ‐2 infection

Pityriasis rosea infection in a COVID ‐19 patient successfully treated with systemic steroid and antihistamine via telemedicine: Literature update of a possible prodromal symptom of an underlying SARS‐CoV ‐2 infection

Post Covid‐19 vaccination papulovesicular pityriasis rosea‐like eruption in a young male

Pityriasis rosea Gibert triggered by SARS-CoV-2 infection

Contact Info

Product

Resources

About